Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pieter van Baal

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Heart (British Cardiac Society)|June 19, 2012
Important cost categories not included: transcatheter aortic valve implantation probably less cost-effectivePieter van Baal
Nederlands Tijdschrift Voor Geneeskunde|April 30, 2015
[Less need for prevention through better care? Towards an effective deployment of preventive and curative care]Pieter van Baal
Pharmacoeconomics|August 2, 2023
Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care CostsWerner Brouwer, Pieter van Baal
Pharmacoeconomics|May 17, 2011
PAID 1.0 in practice: a brief clarification regarding its possibilities and limitationsPieter van Baal, Werner Brouwer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 29, 2024
Drug Pricing, Patient Welfare, and Cost-Effectiveness AnalysisPieter van Baal, Pedro Pita Barros
Pharmacoeconomics|April 19, 2013
Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et AlPieter van Baal, David Meltzer, Werner Brouwer
Cost Effectiveness and Resource Allocation : C/E|March 20, 2020
Costs and benefits of early response in the Ebola virus disease outbreak in Sierra LeoneKlas Kellerborg, Werner Brouwer, Pieter van Baal
Health Economics|December 24, 2014
Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness AnalysisPieter van Baal, David Meltzer, Werner Brouwer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 2, 2022
Quality-Adjusted Life-Years Lost Due to COVID-19 Mortality: Methods and Application for The NetherlandsBram Wouterse, Frederique Ram, Pieter van Baal
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|August 14, 2020
Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literatureKlas Kellerborg, Werner Brouwer, Pieter van Baal
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Heart (British Cardiac Society)|June 19, 2012
Important cost categories not included: transcatheter aortic valve implantation probably less cost-effectivePieter van Baal
Nederlands Tijdschrift Voor Geneeskunde|April 30, 2015
[Less need for prevention through better care? Towards an effective deployment of preventive and curative care]Pieter van Baal
Pharmacoeconomics|August 2, 2023
Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care CostsWerner Brouwer, Pieter van Baal
Pharmacoeconomics|May 17, 2011
PAID 1.0 in practice: a brief clarification regarding its possibilities and limitationsPieter van Baal, Werner Brouwer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 29, 2024
Drug Pricing, Patient Welfare, and Cost-Effectiveness AnalysisPieter van Baal, Pedro Pita Barros
Pharmacoeconomics|April 19, 2013
Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et AlPieter van Baal, David Meltzer, Werner Brouwer
Cost Effectiveness and Resource Allocation : C/E|March 20, 2020
Costs and benefits of early response in the Ebola virus disease outbreak in Sierra LeoneKlas Kellerborg, Werner Brouwer, Pieter van Baal
Health Economics|December 24, 2014
Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness AnalysisPieter van Baal, David Meltzer, Werner Brouwer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 2, 2022
Quality-Adjusted Life-Years Lost Due to COVID-19 Mortality: Methods and Application for The NetherlandsBram Wouterse, Frederique Ram, Pieter van Baal
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|August 14, 2020
Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literatureKlas Kellerborg, Werner Brouwer, Pieter van Baal
Pageof 5